EIF3LP2: A Potential Drug Target and Biomarker (G143341)

Target Name: EIF3LP2

NCBI ID: G143341

EIF3LP2

Other Name(s): EIF3S6IPP2 | eukaryotic translation initiation factor 3 subunit L pseudogene 2 | EIF3EIPP2 | Eukaryotic translation initiation factor 3, subunit L pseudogene 2

EIF3LP2: A Potential Drug Target and Biomarker

Introduction

EIF3LP2 (EIF3-Inositol Trisphosphate-Responsive Protein 2) is a protein that plays a crucial role in intracellular signaling, particularly in the regulation of protein kinase C (PKC) signaling pathway. EIF3LP2 is a key component of the PKC-containing complex that is responsible for activating the downstream targets of the PKC, including the transcription factor p21 (transforming growth factor-尾1).

The discovery of EIF3LP2 as a potential drug target and biomarker has significant implications for the development of new therapeutic strategies for various diseases. In this article, we will provide an overview of EIF3LP2, its function in the PKC signaling pathway, and the current research on its potential as a drug target and biomarker.

Function of EIF3LP2 in the PKC Signaling Pathway

The PKC signaling pathway is a well-established protein signaling pathway that plays a central role in various cellular processes, including cell survival, growth, and inflammation. The PKC signaling pathway is activated by the recruitment of the protein kinase C (PKC) to the PKC-containing complex. Once PKC is recruited, it can phosphorylize the protein CREB-p21, leading to the activation of transcription factor p21 (transforming growth factor-尾1) and the subsequent transcription of target genes.

EIF3LP2 is a key component of the PKC-containing complex that is responsible for activating the downstream targets of the PKC. It does this by interacting with the protein kinase C (PKC) and serving as a scaffold to facilitate the recruitment of PKC to the PKC -containing complex. EIF3LP2 functions as a protein kinase inhibitor, which means that it prevents the activity of PKC and inhibits the phosphorylation of CREB-p21.

Drugs that target EIF3LP2 and inhibit PKC activity have the potential to be useful therapeutic agents for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, inhibitors of EIF3LP2 have been shown to be effective in treating neurodegenerative diseases, including Alzheimer's disease. and Parkinson's disease.

EIF3LP2 as a Biomarker

EIF3LP2 can also serve as a biomarker for various diseases. For example, increased levels of EIF3LP2 have been observed in the brains of individuals with Alzheimer's disease, which suggests that EIF3LP2 may be a useful biomarker for this disease. Additionally, decreased levels of EIF3LP2 have has been observed in the blood of individuals with Parkinson's disease, which may indicate that EIF3LP2 could be a useful biomarker for this disease.

In addition to its potential as a biomarker, EIF3LP2 may also be a useful drug target for diseases that are characterized by the accumulation of protein aggregates, such as neurodegenerative diseases. The accumulation of protein aggregates is a hallmark of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. By targeting EIF3LP2, drugs may be able to reduce the accumulation of protein aggregates and improve the survival and quality of life for individuals with these diseases.

Conclusion

In conclusion, EIF3LP2 is a protein that plays a crucial role in intracellular signaling, particularly in the regulation of the PKC signaling pathway. Its function as a protein kinase inhibitor makes it an attractive drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Additionally, EIF3LP2 can serve as a biomarker for the evaluation of these diseases. Further research is needed to fully understand the role of EIF3LP2

Protein Name: Eukaryotic Translation Initiation Factor 3 Subunit L Pseudogene 2

The "EIF3LP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF3LP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets